Cogent Biosciences (COGT) Other Working Capital Changes (2017 - 2026)
Cogent Biosciences (COGT) posted quarterly Other Working Capital Changes of -$312000.0 for Q3 2020, up 31.88% year-over-year from -$236582.8 in Q4 2019, and up 41.02% quarter-over-quarter from -$529000.0 in Q2 2020.
Powered by 
Analysis
Cogent Biosciences (COGT) Other Working Capital Changes (2017 - 2026) Analysis & Trends
Cogent Biosciences (COGT) has reported Other Working Capital Changes for 3 consecutive years, with -$312000.0 the latest figure, recorded in Q3 2020.
- In Q3 2020, Other Working Capital Changes rose 31.88% year-over-year to -$312000.0; the TTM figure through Dec 2020 stood at -$1.3 million (up 92.09% YoY), while the FY2020 annual figure was -$1.3 million, up 92.09% from the prior year.
- Other Working Capital Changes improved to -$312000.0 in Q3 2020 per COGT's latest filing, from -$529000.0 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $4.3 million in Q4 2024 and bottomed at -$3.0 million in Q3 2025.
- Historically, Other Working Capital Changes has averaged $443785.7 across 5 years, with a median of $58500.0 in 2023.
- Annual changes were most pronounced in 2019 — Other Working Capital Changes plunged 527.14% — and 2020, when it soared 69.94%.
- Cogent Biosciences' Other Working Capital Changes stood at -$2.1 million in 2018, then slumped by 527.14% to -$13.4 million in 2019, then surged by 97.67% to -$312000.0 in 2020.
- Business Quant data shows COGT's Other Working Capital Changes at -$312000.0 in Q3 2020, -$529000.0 in Q2 2020, and -$474000.0 in Q1 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Cogent Biosciences | 5.94 Bn | 5.94 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -297,000.00 |
| Jun 30, 2026 | -297,000.00 |
| Mar 31, 2026 | 1.84 Mn |
| Mar 31, 2026 | 1.84 Mn |
| Dec 31, 2025 | 3.24 Mn |
| Dec 31, 2025 | 3.24 Mn |
| Sep 30, 2025 | -806,000.00 |
| Sep 30, 2025 | -806,000.00 |
| Jun 30, 2025 | -63,000.00 |
| Jun 30, 2025 | -63,000.00 |
| Mar 31, 2025 | -2.17 Mn |
| Mar 31, 2025 | -2.17 Mn |
| Dec 31, 2024 | 3.39 Mn |
| Dec 31, 2024 | 3.39 Mn |
| Sep 30, 2024 | -746,000.00 |
| Sep 30, 2024 | -746,000.00 |
| Jun 30, 2024 | 592,000.00 |
| Jun 30, 2024 | 592,000.00 |
| Mar 31, 2024 | 1.10 Mn |
| Mar 31, 2024 | 1.10 Mn |